Depression is an usual finding in patients suffering from chronic Hepatitis C.
Development of moderate to severe depressive symptoms occurs frequently during pegylated interferon/ribavirin treatment and is generally predicted by baseline depression scores.
Obese patients are twice as likely to suffer from anxiety, impaired social interaction, and depression when compared with the non-obese population.
|35% were non-responders to selective serotonin reuptake inhibitors|
|Journal of Viral Hepatitis|
Dr Tarantino and colleagues from Italy evaluated the efficacy of a pharmacological treatment of depression in 68 obese patients with chronic Hepatitis C.
The patients were either under or no antiviral therapy, and were enrolled into an open, controlled pilot study.
The patients were divided in 2 groups.
There were 37 patients in Group 1 on 'Selective Serotonin Reuptake Inhibitors plus support', with individual titration of medication to adequate side-effects.
A further 31 patients in Group 2 were 'on only support'.
Both groups were well balanced for gender, age and antiviral treatment.
The researchers found that the selected patients had, at entry, a Beck Depression Inventory score of 25.
Therapeutic successful outcomes were statistically more frequent in the antidepressant drug-treated group, all predicted by dose of selective serotonin reuptake inhibitors.
The research team noted that 35% of patients were non-responders to selective serotonin reuptake inhibitors.
Dr Tarantino's team concluded, "The drug tolerability was good."
"Nearly 20% of patients were responders to only support."